All In Biotech

Drug Trial Radar · NCT07166081

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

A Phase 1, Double-Blind, Randomized, Ascending-Dose, Placebo-Controlled, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets Orally Administered in Non-diabetic Overweight or Obese Adult Subjects

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Aug 11, 2025

Primary completion

Mar 16, 2026

Study completion Jul 15, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult subjects.

Conditions

  • Non-diabetic Overweight or Obese

Interventions

  • BGM0504Drug

    Administered orally

  • BGM0504Drug

    Administered orally

  • BGM0504Drug

    Administered orally

  • PlaceboDrug

    Administered orally

  • BGM0504Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment adverse eventsTime frame: 11 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron CPC, Inc

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.